EpistaxisNCT07531472
Outcome of Hyaluronic Acid Gel Versus Petroleum Jelly in Treatment of Epistaxis
A study testing Hyaluronic Acid Gel and Petroleum jelly in people with Epistaxis, run by Assiut University.
Trial summary
The aim of this study is to compare the efficacy of Hyaluronic Acid Gel with Petroleum Jelly in treatment of epistaxis. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Epistaxis
- What is being tested?
- Hyaluronic Acid Gel and Petroleum jelly
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- 1 May 2026to 1 Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patients with anterior localized idiopathic epistaxis
Who cannot join
- Patients wit secondary epistaxis (posttraumatic, postoperative, tumoral).
- During pregnancy.
- Patients wit major systemic disease (Blood Disease, Hypertension).
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The aim of this study is to compare the efficacy of Hyaluronic Acid Gel with Petroleum Jelly in treatment of epistaxis.
Read the detailed description
- Epistaxis is one of the most common otorhinolaryngologic emergencies. It affects up to 60% of the population during their lifetime, with 6% requiring medical attention. The greatest peaks in the overall incidence occur in individuals under 10 years of age and over 40 years of age.
- In 1879, James Little identified an arterial plexus on the anterior septum as a frequent site of bleeding and the same plexus was described one year later by Kiesselbach. As a result of these descriptions, the area most frequently implicated in epistaxis is known as Little's area or Kiesselbach plexus which is anatomically formed by the anastomosis between the terminal branches of the external and internal carotid arteries (Anterior ethmoidal artery, Septal branch of Superior labial artery, Septal branch of Sphenopalatine artery, Septal branch of Greater palatine artery) .
- The most common etiology of epistaxis is idiopathic in 80%-90% of cases, no precipitating causes can be identified. Of the other identifiable local causes of epistaxis, the most frequent are trauma, nasal neoplasm, iatrogenic or due to systemic factors (hypertension, coagulopathy, inflammatory conditions, infectious diseases, vessel wall fibrosis in associated with ageing), use of drugs (anticoagulant, antiplatelet, nonsteroidal anti-inflammatory nasal sprays) and congenital nasal septal abnormalities .
- Management of recurrent anterior epistaxis can be done by cautery (chemical or electrical), anterior nasal packing or Surgical therapy if the other methods failed .
- This protocol outlines standardized guidelines for the use of Hyaluronic Acid (HA) in epistaxis management for nasal mucosal hydration, healing, and recurrence prevention. It is suitable for use in ENT clinics, emergency departments, and hospital wards.
- Mechanism of action of Hyaluronic acid:
- Hydration: Binds large amounts of water, maintaining skin moisture and elasticity.
- Wound healing: Promotes keratinocyte and fibroblast proliferation, enhancing tissue repair and regeneration.
- Anti-inflammatory effect: Reduces inflammatory cytokines and modulates immune response.
- Barrier protection: Forms a protective layer that prevents water loss and protects against irritants and microbes.
- Collagen stimulation: Supports collagen synthesis and improves skin structure.
- Antioxidant action: Scavenges free radicals, reducing oxidative damage.
- Conditions
- Epistaxis
- Being tested
- Hyaluronic Acid Gel, Petroleum jelly
- Medical subject headings
- Epistaxis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Hyaluronic Acid GelDrug
"Topical hyaluronic acid gel will be applied to the nasal mucosa of participants for the treatment of epistaxis. The gel will be administered according to the study protocol and frequency, and outcomes will be assessed throughout the study period."
Petroleum jellyDrug
"Topical petroleum jelly will be applied to the nasal mucosa of participants for the treatment of epistaxis. The application will follow the study protocol, and outcomes will be monitored and recorded over the study period."
| Study group | Role | What they receive |
|---|---|---|
| Hyaluronic Acid Gel | Experimental | "Participants in this group will receive topical hyaluronic acid gel applied to the nasal mucosa for the treatment of epistaxis. The application will be done as per the study protocol, and outcomes will be monitored over the study period." Receives: Drug: Hyaluronic Acid Gel |
| Petroleum Jelly | Experimental | "Participants in this group will receive topical petroleum jelly applied to the nasal mucosa for the treatment of epistaxis. The application will follow the study protocol, and outcomes will be monitored over the study period." Receives: Drug: Petroleum jelly |
What is being measured
The primary outcome is the main question the study is designed to answer.
To compare the recurrence rate of epistaxis between the two groups
"Proportion of participants whose epistaxis stops completely within 7 days of treatment application."
Measured: 14 days
Secondary outcomes (4)
To assess time to symptom resolution
"Time in minutes or hours from first application to complete cessation of nasal bleeding."
Measured: Within 24 hours
To evaluate mucosal healing (endoscopic findings)
"Assessment of nasal mucosa healing using endoscopic examination after application of hyaluronic acid gel or petroleum jelly, scored according to a standardized mucosal healing scale."
Measured: 7-14 days
To assess patient comfort and compliance
"Measured using a standardized questionnaire or visual analog scale during the treatment period."
Measured: 7 days
To record adverse effects
"Incidence of local irritation, allergic reactions, or other side effects related to the topical intervention."
Measured: 14 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Apr 2026
- Study start1 May 2026 (estimated)
- Primary completion1 Apr 2028 (estimated)
- Study completion1 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EpistaxisStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- "Participants will be assigned to one of two parallel groups to receive either topical hyaluronic acid gel or petroleum jelly for the treatment of epistaxis, and outcomes will be compared between groups."
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Marina Emil Kamal Kaml, Assiut University
- Investigators
- Ahmed AbdelAleem AbdelWahab, Prof, Study director
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07531472
- Sponsor's protocol ID
- HAvsPJ-EPI
- Status last verified
- Apr 2026
- First submitted
- 9 Apr 2026
- Last updated
- 22 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Outcome of Hyaluronic Acid Gel Versus Petroleum Jelly in Treatment of Epistaxis
- ClinicalTrials.gov ID
- NCT07531472
- Acronym / sponsor ID
- HAvsPJ-EPI
- Conditions
- Epistaxis
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 May 2026 (estimated)
- Primary completion
- 1 Apr 2028 (estimated)
- Study completion
- 1 Jun 2028 (estimated)
- First posted
- 15 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to compare the efficacy of Hyaluronic Acid Gel with Petroleum Jelly in treatment of epistaxis.
Detailed description
- Epistaxis is one of the most common otorhinolaryngologic emergencies. It affects up to 60% of the population during their lifetime, with 6% requiring medical attention. The greatest peaks in the overall incidence occur in individuals under 10 years of age and over 40 years of age.
- In 1879, James Little identified an arterial plexus on the anterior septum as a frequent site of bleeding and the same plexus was described one year later by Kiesselbach. As a result of these descriptions, the area most frequently implicated in epistaxis is known as Little's area or Kiesselbach plexus which is anatomically formed by the anastomosis between the terminal branches of the external and internal carotid arteries (Anterior ethmoidal artery, Septal branch of Superior labial artery, Septal branch of Sphenopalatine artery, Septal branch of Greater palatine artery) .
- The most common etiology of epistaxis is idiopathic in 80%-90% of cases, no precipitating causes can be identified. Of the other identifiable local causes of epistaxis, the most frequent are trauma, nasal neoplasm, iatrogenic or due to systemic factors (hypertension, coagulopathy, inflammatory conditions, infectious diseases, vessel wall fibrosis in associated with ageing), use of drugs (anticoagulant, antiplatelet, nonsteroidal anti-inflammatory nasal sprays) and congenital nasal septal abnormalities .
- Management of recurrent anterior epistaxis can be done by cautery (chemical or electrical), anterior nasal packing or Surgical therapy if the other methods failed .
- This protocol outlines standardized guidelines for the use of Hyaluronic Acid (HA) in epistaxis management for nasal mucosal hydration, healing, and recurrence prevention. It is suitable for use in ENT clinics, emergency departments, and hospital wards.
- Mechanism of action of Hyaluronic acid:
- Hydration: Binds large amounts of water, maintaining skin moisture and elasticity.
- Wound healing: Promotes keratinocyte and fibroblast proliferation, enhancing tissue repair and regeneration.
- Anti-inflammatory effect: Reduces inflammatory cytokines and modulates immune response.
- Barrier protection: Forms a protective layer that prevents water loss and protects against irritants and microbes.
- Collagen stimulation: Supports collagen synthesis and improves skin structure.
- Antioxidant action: Scavenges free radicals, reducing oxidative damage.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- "Participants will be assigned to one of two parallel groups to receive either topical hyaluronic acid gel or petroleum jelly for the treatment of epistaxis, and outcomes will be compared between groups."
| Arm | Type | Receives |
|---|---|---|
| Hyaluronic Acid Gel | Experimental | Drug: Hyaluronic Acid Gel"Participants in this group will receive topical hyaluronic acid gel applied to the nasal mucosa for the treatment of epistaxis. The application will be done as per the study protocol, and outcomes will be monitored over the study period." |
| Petroleum Jelly | Experimental | Drug: Petroleum jelly"Participants in this group will receive topical petroleum jelly applied to the nasal mucosa for the treatment of epistaxis. The application will follow the study protocol, and outcomes will be monitored over the study period." |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Patients with anterior localized idiopathic epistaxis
Key exclusion criteria (3 listed)
- Patients wit secondary epistaxis (posttraumatic, postoperative, tumoral).
- During pregnancy.
- Patients wit major systemic disease (Blood Disease, Hypertension).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Hyaluronic Acid Gel"Topical hyaluronic acid gel will be applied to the nasal mucosa of participants for the treatment of epistaxis. The gel will be administered according to the study protocol and frequency, and outcomes will be assessed throughout the study period." | Drug | Hyaluronic Acid Gel |
| Petroleum jelly"Topical petroleum jelly will be applied to the nasal mucosa of participants for the treatment of epistaxis. The application will follow the study protocol, and outcomes will be monitored and recorded over the study period." | Drug | Petroleum Jelly |
Primary outcome
To compare the recurrence rate of epistaxis between the two groups
Time frame: 14 days
"Proportion of participants whose epistaxis stops completely within 7 days of treatment application."
4 secondary outcomes
To assess time to symptom resolution
Time frame: Within 24 hours
To evaluate mucosal healing (endoscopic findings)
Time frame: 7-14 days
To assess patient comfort and compliance
Time frame: 7 days
To record adverse effects
Time frame: 14 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Apr 2026.
- Daniel B and Nick S,(2010) Epistaxis; Cummings Otolaryngology head and neck surgery, volume 1, ch45:p682. fifth edition.Link provided by the sponsor.
- Comparison of local sclerotherapy with Lauromacrogol versus nasal packing in the treatment of anterior epistaxis. Clinical and Experimental Otorhinolaryngology.2016;9:131-135.Link provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Epistaxis
Not yet recruitingPhase 1
Topical TOR-582 Treatment of Epistaxis in HHT
Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis
Active, not recruitingPhase 1/2
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary Hemorrhagic Telangiectasia
Not yet recruitingPhase 2
Effect of Vitamin C Administration on Intraoperative Bleeding in Patients Undergoing Sinusoscopy
Chronic Rhinosinusitis, Intraoperative Bleeding
Recruiting
Comparative Study - Transseptal Suture Technique Verses Anterior Nasal Packing After Septoplasty
Deviated Nasal Septum, Postoperative Nasal Pain
RecruitingPhase 3
RADA16 for Adult Tonsillectomy
Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ahmed AbdelAleem AbdelWahab, Prof study director
Questions about this trial
What is this clinical trial studying?
A study testing Hyaluronic Acid Gel and Petroleum jelly in people with Epistaxis, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marina Emil Kamal Kaml, M.B.B.CH (+201274047194, Mareena.20134245@med.aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To compare the recurrence rate of epistaxis between the two groups (time frame: 14 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2026.